The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

By Z. Younossi, D. Blissett, Robert S Blissett, L. Henry, M. Stepanova, Youssef Younossi, A. Racila, S. Hunt, R. Beckerman. Hepatology, 2016

1,135 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Systematic reviews and meta-analyses (2009, background): “27,39,45 Regression Several studies analyzed the impact of treatment interventions on disease progression, although the way this was implemented in the model varied.”
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019, background): “2674 incidence, and progressiveness must be coupled with its tremendous economic burden and its negative effects on patient-reported outcomes (PROs).(14) Currently, there is no approved drug regimen to treat NASH.”
Current and future pharmacological therapies for NAFLD/NASH (2017, background): “Economical cost and benefit should also be balanced [107].”
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “Overall, NAFLD is becoming a relevant cause of HCC in developed regions and it is estimated that in the USA between 500,000 and 900,000 new cases of HCC may develop as a result of the high prevalence of metabolic syndrome and NAFLD.(47) In NAFLD, the reported HCC incidence is very heterogeneous, ran”
Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “Modified from.(59) NAFLD, non-alcoholic fatty liver disease.”